Patient and transplantation characteristics
| Characteristic . | Splenectomy . | |
|---|---|---|
| Yes (n = 11) . | No (n = 15) . | |
| Diagnosis (no. patients) | ||
| AMM | 7 | 7 |
| MF after ET or P vera | 2 | 7 |
| AMM with excess blasts | 2 | 1 |
| Patient age (y), range (median) | 26-59 (44) | 18-54 (36) |
| Patient sex (male/female; no. patients) | 5/6 | 9/6 |
| Duration of disease (mo), range (median) | 4-252 (37.5) | 1-144 (14) |
| Therapy before transplantation (no. patients) | ||
| None | 0 | 2 |
| RBC transfusion | 7 | 8 |
| Platelet transfusions | 0 | 3 |
| Hydroxyurea | 0 | 2 |
| Splenectomy | 11 | 0 |
| Donor (no. patients) | ||
| HLA-identical sibling | 4 | 8 |
| HLA-nonidentical, related | 3 | 3 |
| HLA-matched, unrelated | 4 | 4 |
| Conditioning regimen (no. patients) | ||
| BUCY (total/targeted)* | 8/5 | 11/8 |
| CYTBI | 1 | 2 |
| BUTBI | 2 | 2 |
| Characteristic . | Splenectomy . | |
|---|---|---|
| Yes (n = 11) . | No (n = 15) . | |
| Diagnosis (no. patients) | ||
| AMM | 7 | 7 |
| MF after ET or P vera | 2 | 7 |
| AMM with excess blasts | 2 | 1 |
| Patient age (y), range (median) | 26-59 (44) | 18-54 (36) |
| Patient sex (male/female; no. patients) | 5/6 | 9/6 |
| Duration of disease (mo), range (median) | 4-252 (37.5) | 1-144 (14) |
| Therapy before transplantation (no. patients) | ||
| None | 0 | 2 |
| RBC transfusion | 7 | 8 |
| Platelet transfusions | 0 | 3 |
| Hydroxyurea | 0 | 2 |
| Splenectomy | 11 | 0 |
| Donor (no. patients) | ||
| HLA-identical sibling | 4 | 8 |
| HLA-nonidentical, related | 3 | 3 |
| HLA-matched, unrelated | 4 | 4 |
| Conditioning regimen (no. patients) | ||
| BUCY (total/targeted)* | 8/5 | 11/8 |
| CYTBI | 1 | 2 |
| BUTBI | 2 | 2 |
AMM, agnogenic myeloid metaplasia; MF, myelofibrosis; BUCY, busulfan (16 mg/kg) + cyclophosphamide (2 × 60 mg/kg); CYTBI, cyclophosphamide (2 × 60 mg/kg) + total body irradiation (6 × 200 cGy); BUTBI, busulfan (7 mg/kg) + total body irradiation (6 × 200 cGy); ET, essential thrombocythemia; P vera, polycythemia vera; RBC, red blood cell; HLA, human leukocyte antigen.
In patients given “targeted” busulfan, the dose was adjusted to a steady-state plasma level of 900 ng/mL.